Takeda Pharmaceutical Company Limited Earnings

Takeda Pharmaceutical Company Limited’s revenue jumped 12.75% since last year same period to $1176038Mn in the Q3 2024. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -2.65% fall in its revenue since last 3-months.

Takeda Pharmaceutical Company Limited’s net profit jumped 291.64% since last year same period to $92046Mn in the Q3 2024. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -3.36% fall in its net profits since last 3-months.

Takeda Pharmaceutical Company Limited’s net profit margin jumped 269.98% since last year same period to 7.83% in the Q3 2024. On a quarterly growth basis, Takeda Pharmaceutical Company Limited has generated -0.74% fall in its net profit margins since last 3-months.

Takeda Pharmaceutical Company Limited’s price-to-earnings ratio after this Q3 2024 earnings stands at 22.05.

Takeda Pharmaceutical Company Limited’s earning per share (EPS) estimates for the current quarter stand at 0.63 - a -99.28% fall from last quarter’s estimates.

Takeda Pharmaceutical Company Limited’s earning per share (EPS) estimates for the current year stand at 0.63.

Takeda Pharmaceutical Company Limited’s earning per share (EPS) jumped 287.55% since last year same period to 29.07 in the Q3 2024. This indicates that the Takeda Pharmaceutical Company Limited has generated 287.55% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Takeda Pharmaceutical Company Limited’s return on assets (ROA) stands at 0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Takeda Pharmaceutical Company Limited’s return on equity (ROE) stands at 0.04.